Small-cell lung cancer is a highly malignant form of lung cancer, also known as oat-cell carcinoma, that accounts for approximately 15% of lung cancer cases. Composed of small, ovoid cells with ...

Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) is a subtype of lung cancer characterized by specific genetic alterations that lead to the overactivity of the ALK protein.

A Chinese player entered the U.S. non-small-cell lung cancer (NSCLC) arena as the U.S. FDA cleared Xcovery Holdings Inc.’s Ensacove (ensartinib) as a first-line therapy for adults with anaplastic ...

for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks an important advancement in ...

Imfinzi for Limited-Stage Small Cell Lung Cancer Imfinzi (durvalumab) was approved for adults with limited-stage ... The FDA has approved Ensacove (ensartinib) for the first-line treatment of adults ...

The University of Michigan Rogel Cancer Center’s Judith Tam ALK [anaplastic lymphoma kinase ... alectinib resistant EML4-ALK positive non-small cell lung cancer (NSCLC) cell lines.